You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):控股子公司藥品獲歐盟上市批准
格隆匯 02-05 19:25

格隆匯2月5日丨復星醫藥(600196.SH)公佈,控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司自主研發的斯魯利單抗注射液(即抗PD-1單抗,歐盟商品名:Hetronifly)聯合卡鉑和依託泊苷適用於廣泛期小細胞肺癌(ES-SCLC)成人患者的一線治療的上市許可申請(MAA)於近日獲歐盟委員會(即EuropeanCommission)批准。據此,該藥品獲得所有歐盟成員國及冰島、列支敦士登和挪威(分別為歐洲經濟區<EEA>國家)的集中上市許可,併成為首個歐盟批准用於廣泛期小細胞肺癌(ES-SCLC)治療的抗PD-1單抗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account